Insider Trading Alert - ICPT, SPTN And CME Traded By Insiders

Yesterday, Aug. 2, 2016, 97 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $43.70 to $50,903,280.00.

Highlighted Stocks Traded by Insiders:

Intercept Pharmaceuticals (ICPT) - FREE Research Report

McMinn Rachel, who is Chief Strategy Officer at Intercept Pharmaceuticals, sold 125 shares at $176.56 on Aug. 2, 2016. Following this transaction, the Chief Strategy Officer owned 13,861 shares meaning that the stake was reduced by 0.89% with the 125-share transaction.

The shares most recently traded at $169.72, down $6.84, or 4.03% since the insider transaction. Historical insider transactions for Intercept Pharmaceuticals go as follows:

  • 4-Week # shares bought: 800
  • 4-Week # shares sold: 1,284
  • 12-Week # shares bought: 800
  • 12-Week # shares sold: 1,535
  • 24-Week # shares bought: 800
  • 24-Week # shares sold: 3,180

The average volume for Intercept Pharmaceuticals has been 516,900 shares per day over the past 30 days. Intercept Pharmaceuticals has a market cap of $4.1 billion and is part of the health care sector and drugs industry. Shares are up 15.86% year-to-date as of the close of trading on Friday.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Currently, there are 8 analysts who rate Intercept Pharmaceuticals a buy, 3 analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ICPT - FREE

TheStreet Quant Ratings rates Intercept Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Intercept Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

SpartanNash (SPTN) - FREE Research Report

Couch David Des, who is VP Chief Info. Officer at SpartanNash, sold 14,092 shares at $32.29 on Aug. 2, 2016. Following this transaction, the VP Chief Info. Officer owned 55,178 shares meaning that the stake was reduced by 20.34% with the 14,092-share transaction.

The shares most recently traded at $31.52, down $0.77, or 2.44% since the insider transaction. Historical insider transactions for SpartanNash go as follows:

  • 4-Week # shares sold: 10,000
  • 12-Week # shares sold: 33,713
  • 24-Week # shares sold: 101,852

The average volume for SpartanNash has been 190,700 shares per day over the past 30 days. SpartanNash has a market cap of $1.2 billion and is part of the services sector and wholesale industry. Shares are up 45.56% year-to-date as of the close of trading on Friday.

SpartanNash Company operates as a grocery distributor and retailer primarily in the United States. The company operates in three segments: Military, Food Distribution, and Retail. The stock currently has a dividend yield of 1.94%. The company has a P/E ratio of 18.5. Currently, there are no analysts who rate SpartanNash a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SPTN - FREE

TheStreet Quant Ratings rates SpartanNash as a buy. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full SpartanNash Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

CME Group (CME) - FREE Research Report

Gepsman Martin J, who is Director at CME Group, sold 500 shares at $102.60 on Aug. 2, 2016. Following this transaction, the Director owned 43,102 shares meaning that the stake was reduced by 1.15% with the 500-share transaction.

Taylor Kimberly S, who is Sr MD Pres Gl Ops Tech & Risk at CME Group, sold 2,300 shares at $102.58 on Aug. 2, 2016. Following this transaction, the Sr MD Pres Gl Ops Tech & Risk owned 103,789 shares meaning that the stake was reduced by 2.17% with the 2,300-share transaction.

Suskind Dennis, who is Director at CME Group, sold 1,000 shares at $102.79 on Aug. 2, 2016. Following this transaction, the Director owned 11,099 shares meaning that the stake was reduced by 8.27% with the 1,000-share transaction.

The shares most recently traded at $103.09, up $0.30, or 0.29% since the insider transaction. Historical insider transactions for CME Group go as follows:

  • 4-Week # shares bought: 1
  • 4-Week # shares sold: 2,300
  • 12-Week # shares bought: 1
  • 12-Week # shares sold: 10,058
  • 24-Week # shares bought: 1
  • 24-Week # shares sold: 25,110

The average volume for CME Group has been 1.4 million shares per day over the past 30 days. CME Group has a market cap of $34.5 billion and is part of the financial sector and financial services industry. Shares are up 12.85% year-to-date as of the close of trading on Friday.

CME Group Inc., through its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. The stock currently has a dividend yield of 2.35%. The company has a P/E ratio of 25.4. Currently, there are 5 analysts who rate CME Group a buy, 2 analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CME - FREE

TheStreet Quant Ratings rates CME Group as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, increase in net income and reasonable valuation levels. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full CME Group Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Let the Najarian Brothers Help You Generate Income With Options

Let the Najarian Brothers Help You Generate Income With Options

All Investors Can Trade Options, Just Ask the Najarian Brothers WATCH VIDEO

All Investors Can Trade Options, Just Ask the Najarian Brothers WATCH VIDEO

Dow Makes Move Higher as Bond Yields Hover Near 3% Threshold

Dow Makes Move Higher as Bond Yields Hover Near 3% Threshold

Aluminum Prices Plummet as U.S. Is Open to Easing Sanctions on Russia's Rusal

Aluminum Prices Plummet as U.S. Is Open to Easing Sanctions on Russia's Rusal

Akorn's Stock Crashes as Germany's Fresenius Ends Takeover Amid Data Allegations

Akorn's Stock Crashes as Germany's Fresenius Ends Takeover Amid Data Allegations